Display options
Filter resources
Text Availability
Article type
Publication date
Showing 1 to 12 of 157 entries
Sorted by: Best Match Show Resources per page
European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986.

European journal of cancer & clinical oncology

Coiffier B, Bosly A, Caligaris-Cappio F, Gisselbrecht C, Patte C, Schaadt M, Symann M.
PMID: 3322847
Eur J Cancer Clin Oncol. 1987 Nov;23(11):1691-5. doi: 10.1016/0277-5379(87)90451-2.

No abstract available.

Plasmapheresis: an effective therapy for cholestatic episodes related to benign recurrent intrahepatic cholestasis?.

Annales de medecine interne

Nakad A, Geubel AP, Lejeune D, Delannoy A, Bosly A, Dive C.
PMID: 3395056
Ann Med Interne (Paris). 1988;139(2):128-30.

No abstract available.

Acute lymphoblastic leukemia in the elderly.

European journal of haematology

Delannoy A, Ferrant A, Bosly A, Chatelain C, Doyen C, Martiat P, Michaux JL, Sokal G.
PMID: 2209825
Eur J Haematol. 1990 Aug;45(2):90-3. doi: 10.1111/j.1600-0609.1990.tb00424.x.

We report our findings in 18 patients with acute lymphoblastic leukemia (ALL) aged 60 years or older. A preleukemic syndrome was observed in 2 patients. Compared to younger adults with ALL, L3 morphology was unexpectedly frequent (4/16). T-ALL was...

Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement.

Cancer genetics and cytogenetics

Cuneo A, Kerim S, Vandenberghe E, Van Orshoven A, Rodhain J, Bosly A, Zachee P, Louwagie A, Michaux JL, Dal Cin P.
PMID: 2790756
Cancer Genet Cytogenet. 1989 Oct 15;42(2):209-19. doi: 10.1016/0165-4608(89)90089-7.

The cytological and cytogenetic features of six patients with myeloid neoplasia and t(6;9)(p23;q34) including a case of acute myelofibrosis (AMF), a refractory anemia with excess of blasts (RAEB), and four cases of acute nonlymphocytic leukemia (ANLL) are described. Two...

Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).

Medical oncology and tumor pharmacotherapy

Weynants P, Humblet Y, Bosly A, Schallier D, Duprez P, Majois F, Beauduin M, Prignot J, Symann M.
PMID: 2178205
Med Oncol Tumor Pharmacother. 1990;7(4):219-22. doi: 10.1007/BF02987098.

Carboplatin, a second generation platinum complex, is less nephrotoxic and emetogenic than its parent compound. We have tested the objective response to and the toxicity of the combination carboplatin 330 mg m-2 on day 1 with etoposide 120 mg...

Adriamycin and adriamycin--DNA in inoperable bronchogenic carcinoma. A randomized study with cyclophosphamide vinblastine.

European journal of cancer

Bosly A, Prignot J, Ledent C, Sokal G, Trouet A.
PMID: 658087
Eur J Cancer. 1978 Jun;14(6):639-44. doi: 10.1016/0014-2964(78)90297-9.

No abstract available.

[Clinical and biological aspects of intensive chemotherapy with autologous bone marrow grafts in small-cell bronchial cancer].

Bulletin et memoires de l'Academie royale de medecine de Belgique

Symann M, Humblet Y, Bosly A.
PMID: 2553180
Bull Mem Acad R Med Belg. 1989;144(3):213-21; discussion 222-3.

Small cell lung cancer (SCLC) is a frequent and aggressive tumor characterized by its major sensitivity to chemotherapy since 80% of the patients respond dramatically to the treatment. Nevertheless, the majority of them eventually die from their cancer. We...

A phase I study of vinblastine tryptophan ester.

Cancer chemotherapy and pharmacology

Ceulemans F, Humblet Y, Bosly A, Symann M, Trouet A.
PMID: 3757158
Cancer Chemother Pharmacol. 1986;18(1):44-6. doi: 10.1007/BF00253062.

Vinblastine tryptophan ester (VTrpE) is a new vinca alkaloid derivative that achieves antitumor activity in a large variety of animal models. In this phase I study the drug was given as an i.v. injection over 5 min, once a...

Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing lymphoid markers.


Cuneo A, Michaux JL, Ferrant A, Van Hove L, Bosly A, Stul M, Dal Cin P, Vandenberghe E, Cassiman JJ, Negrini M.
PMID: 1732012
Blood. 1992 Feb 01;79(3):720-7.

Cytogenetic, biomolecular, and clinicopathologic features were retrospectively studied in 34 adult patients with acute myelogenous leukemia expressing one or more of the following lymphoid-associated markers (LMs): CD7, CD2, CD10, CD19, CD22, TdT. Six patients showed 11q23 rearrangements (group I);...

A phase II study of vindesine in patients with hematological malignancies.

Biomedicine / [publiee pour l'A.A.I.C.I.G.]

Hulhoven R, Michaux JL, Cornu G, Ferránt A, Bosly A, Delannoy A, Sokal G.
PMID: 6931617
Biomedicine. 1980 Apr;33(2):31-2.

A phase II protocol associating vindesine and prednisone was used in 47 hematological patients of whom 40 were evaluable. The best results were achieved in relapses of childhood's ALL, with a high proportion of complete remissions and in blastic...

Secondary neoplasms in two patients treated with purine analogues.

Nouvelle revue francaise d'hematologie

Schlaifer D, Riga-Huguet F, Pris J, Brousset P, Delannoy A, Bosly A.
PMID: 7971258
Nouv Rev Fr Hematol. 1994 Aug;36(4):341.

No abstract available.

2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).


Delannoy A, Martiat P, Gala JL, Deneys V, Ferrant A, Bosly A, Schieff JM, Michaux JL.
PMID: 7630184
Leukemia. 1995 Jul;9(7):1130-5.

The encouraging therapeutic results attained with the purine analogue CdA in patients with previously treated CLL prompted us to assess its potential in untreated CLL patients. Nineteen patients, 13 males and six females, median age 65 years (range 27-75),...

Showing 1 to 12 of 157 entries